Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis

Abstract

BackgroundY-box binding protein 1 (YB-1) belongs to the cold shock domain protein family involved in transcription and translation. We conducted a meta-analysis of the association between YB-1 expression and the survival and clinicopathological features in NSCLC.MethodsPubMed and Embase were searched to identify studies that evaluated the YB-1 expression (by immunohistochemistry) and overall survival (OS) in NSCLC. Hazard ratios (HRs) and 95% confidence intervals (CI) of OS were pooled. Odds ratios (ORs) of clinicopathological features were computed. Meta-analysis was performed using STATA 12.0 software.ResultsData on 692 NSCLC patients were collected from six eligible studies. Meta-analysis revealed that YB-1 was associated with worse OS (HR = 1.59, 95% CI [1.27, 2.00], P < 0.001, fixed effect), tumor stage (OR = 0.43, 95% CI [0.22-0.82], P = 0.01, random effect), and depth of invasion (OR = 0.37, 95%CI [0.22-0.63], P < 0.001, fixed effect). A subgroup was analyzed by IHC staining to determine the location of YB-1 positive expression. Poor OS was observed in nucleus staining (pooled HR = 1.86, 95% CI [1.41, 2.45], P < 0.001). However, no statistical significance was observed in combined cytoplasmic and nuclear staining (pooled HR = 1.14, 95% CI [0.76, 1.72], P = 0.536).ConclusionsMeta-analysis indicated that YB-1 overexpression is correlated with worse OS and clinicopathological features in NSCLC. Subgroup analysis revealed that the nucleus expression of YB-1 may be more closely associated with NSCLC prognosis than cytoplasmic expression.

Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma

“…Analysis of TCGA data shows that elevated YBX1 expression was highly prognostic in a cohort of 1,926 NSCLC patients (Győrffy et al, 2013; Figure 1D) and in 83 mesothelioma patients (Goswami and Nakshatri, 2014; Figure 1E). This supports the results of a recent meta-analysis of data from 692 NSCLC patients which found that high YB-1 protein expression significantly correlated with poorer overall survival and clinicopathological features (Jiang et al, 2017). YB-1 is overexpressed in mesothelioma compared to non-malignant mesothelial cells in vitro (Johnson et al, 2018) and a small study of 33 MPM patients showed a trend toward higher YB-1 expression in sarcomatoid MPM tumors, which are associated with shorter survival (Iwanami et al, 2014).…”

“…Analysis of TCGA data demonstrate that high levels of YBX1 mRNA correlate significantly with poor prognosis in NSCLC and MPM patients (Figures 1D,E). YB-1 protein has been correlated with poor prognosis previously (Shibahara et al, 2001; Gessner et al, 2004), supported by a recent meta-analysis of six studies covering data on 692 NSCLC patients, where YB-1 was associated with worse overall survival, tumor stage and depth of invasion (Jiang et al, 2017). A study in MPM patients also supports the TCGA data (albeit tentatively due to the low number of patients in the cohort) (Iwanami et al, 2014).…”

Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers

“…YB-1 is one of the rare proteins that regulates the cellular signaling pathways underlying nearly every cancer hallmark [ 2 , 3 ]. As both a cytoplasmic and nuclear protein, YB-1 is highly expressed in different cancer types, such as breast, lung, colorectal, melanocytic, prostate, ovary, and bone cancer [ 2 , 4 , 5 , 6 , 7 ]. In breast carcinomas, expression of cytoplasmic YB-1 has been shown to be associated with tumor aggressiveness, and nuclear localization was shown to be a predictive marker of recurrence after chemo- and radiotherapy [ 8 ].…”

Secreted protein YB-1 and its prognostic significance

“…Высокая экспрессия этого гена ассо-циирована с ухудшением показателя безрецидивной выживаемости больных РМЖ [12], а также больных с другими новообразованиями [13,14]. Кроме того, белок YB-1 является потенциальной мишенью для тар-гетной терапии [15].…”